$5.36
4.08% day before yesterday
Nasdaq, Nov 26, 10:00 pm CET
ISIN
US8051111016
Symbol
SVRA

Savara, Inc. Stock price

$5.36
+0.98 22.37% 1M
+2.52 88.73% 6M
+2.29 74.59% YTD
+1.90 54.91% 1Y
+3.92 272.22% 3Y
+4.07 315.50% 5Y
-24.04 81.77% 10Y
-4,684.64 99.89% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
+0.21 4.08%
ISIN
US8051111016
Symbol
SVRA
Industry

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$996.0m
Net debt
positive
Cash
$124.4m
Shares outstanding
172.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
11.6
Financial Health
Equity Ratio
80.5%
Return on Equity
-56.0%
ROCE
-98.0%
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-121.6m | $-39.0m
EBIT
$-121.7m | $-119.0m
Net Income
$-115.6m | $-91.7m
Free Cash Flow
$-99.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-37.3% | 62.1%
EBIT
-37.3% | -15.6%
Net Income
-40.8% | 4.5%
Free Cash Flow
-21.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.5
FCF per Share
$-0.6
Short interest
10.5%
Employees
59
Rev per Employee
$0.0
Show more

Is Savara, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Savara, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Savara, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Savara, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Savara, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 37 37
70% 70%
-
- Research and Development Expense 84 84
24% 24%
-
-122 -122
37% 37%
-
- Depreciation and Amortization 0.13 0.13
8% 8%
-
EBIT (Operating Income) EBIT -122 -122
37% 37%
-
Net Profit -116 -116
41% 41%
-

In millions USD.

Don't miss a Thing! We will send you all news about Savara, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Savara, Inc. Stock News

Neutral
Business Wire
7 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host one on one meetings and participate in fireside chats at two upcoming healthcare conferences. Fireside Chats: Piper Sandler 37th Annual Healthcare Conference December 2, 2025, 2:30pm...
Positive
Seeking Alpha
12 days ago
Savara, Inc. has rebounded strongly after an FDA setback, aligning on BLA resubmission for molgramostim, its sole clinical candidate for aPAP. Molgramostim showed strong DLCO results in IMPALA-2, with a notable reduction in whole lung lavage need, addressing a $2B+ U.S. market. SVRA holds $125M+ in cash, recently raised $140M, and analysts unanimously rate it a buy, projecting $400M in 2030 sales.
Neutral
Business Wire
15 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2025. “Our recent strategic financings further strengthen our balance sheet, significantly increase our cash runway, and allow us to accelerate our investment in preparing...
More Savara, Inc. News

Company Profile

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Head office United States
CEO Matthew Pauls
Employees 59
Founded 1995
Website savarapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today